LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

LLY

1,021.76

-0.21%↓

JNJ

199.29

+1.67%↑

ABBV

233.81

+0.62%↑

UNH

320.41

-0.3%↓

AZN

89.34

+0.22%↑

Strona główna・Stock List・Altimmune Inc

Altimmune Inc

Closed

4.18 0.48

Buy Sell

Overview

Share price change

24h

Current

Min

4.06

Max

4.21

Key metrics
By Trading Economics
Income	3.1M -19M
Sales	5K
Profit margin	-380,280
Employees	59
EBITDA	2.1M -21M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+305.73% upside

Market Stats
By TradingEconomics
Market Cap	95M 444M
Previous open	3.7
Previous close	4.18

Technical Score

By Trading Central

Confidence

Bullish Evidence

5.365 / 6.0486 Support & Resistance

Altimmune Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

17 lis 2025, 18:59 UTC

Major Market Movers

Medicus Pharma Shares Rise After Filing of FDA Priority-Voucher Application

17 lis 2025, 23:40 UTC

Market Talk

Gold Consolidates Amid Mixed Signals -- Market Talk

17 lis 2025, 23:34 UTC

Market Talk

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

17 lis 2025, 22:58 UTC

Market Talk

RBA's Easing Cycle Is Done, TD Securities Says -- Market Talk

17 lis 2025, 22:46 UTC

Market Talk

Risk Assets Set to Have a Strong 2026 -- Market Talk

17 lis 2025, 22:06 UTC

Acquisitions, Mergers, Takeovers

Constellation Software's Harris Operating Group Completes Agreement To Acquire TECVIA Holding GmbH >CSU.T

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q Rev $2.6B >TCOM

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q Adj EPS $3.87 >TCOM

17 lis 2025, 22:02 UTC

Earnings

Trip.com Group 3Q EPS $4.02 >TCOM

17 lis 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

17 lis 2025, 21:40 UTC

Earnings

James Hardie Industries 2Q Adj EPS 26c >JHX

17 lis 2025, 21:40 UTC

Earnings

James Hardie Industries 2Q Loss/Shr 10c >JHX

17 lis 2025, 21:39 UTC

Earnings

James Hardie Industries 2Q Sales $1.29B >JHX

17 lis 2025, 21:38 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 21:38 UTC

Earnings

XPeng Earnings Beat Wall Street Estimates. Why the Stock Is Falling. -- Barrons.com

17 lis 2025, 21:10 UTC

Earnings

XP Inc. 3Q EPS BRL2.47 >XP

17 lis 2025, 21:10 UTC

Earnings

XP Inc. 3Q Rev BRL4.67B >XP

17 lis 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Retreats on Milder Weather Outlook -- Market Talk

17 lis 2025, 20:12 UTC

Market Talk

Easing Underlying Inflation in Canada Seen Leaving Door Open to Rate Cuts Next Year -- Market Talk

17 lis 2025, 20:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

17 lis 2025, 20:09 UTC

Market Talk

Latest Canadian Inflation Data Supports View BoC is Done Cutting Rates This Cycle -- Market Talk

17 lis 2025, 19:29 UTC

Market Talk

Gold Slide Continues to Start Week -- Market Talk

17 lis 2025, 19:16 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 18:20 UTC

Acquisitions, Mergers, Takeovers

Johnson & Johnson Will Buy Cancer Drugmaker Halda Therapeutics for $3.1 Billion -- Barrons.com

17 lis 2025, 16:45 UTC

Acquisitions, Mergers, Takeovers

Oil Giant TotalEnergies Is Betting Big on Electricity -- Update

17 lis 2025, 16:16 UTC

Earnings

Acquisitions, Mergers, Takeovers

These Stocks Are Moving the Most Today: Alphabet, Apple, Dell, HPE, Nvidia, XPeng, Tesla, Quantum Computing, and More -- Barrons.com

17 lis 2025, 16:15 UTC

Earnings

Luckin, a Chinese Challenger to Starbucks, Aims to Return to U.S. Stock Market -- WSJ

17 lis 2025, 15:40 UTC

Acquisitions, Mergers, Takeovers

Strategy Is in the Crosshairs of Crypto Investors. It Bought More Bitcoin Anyway. -- Barrons.com

17 lis 2025, 15:22 UTC

Acquisitions, Mergers, Takeovers

Alphabet Stock Pops After Berkshire Takes Stake. Why Buffett Might Be Buying. -- Barrons.com

17 lis 2025, 15:19 UTC

Market Talk

Deutsche Bank's Strategic Plan Looks a Tad Underwhelming -- Market Talk

Peer Comparison

Price change

Altimmune Inc Forecast

Price Target

By TipRanks

305.73% upside

12 Months Forecast

Average 17 USD 305.73%

High 25 USD

Low 12 USD

Based on 4 Wall Street analysts offering 12 month price targets forAltimmune Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

4 ratings

Buy

Hold

Sell

Based on 4 analysts giving stock ratings to Altimmune Inc - Dist in the past 3 months.

Technical Score

By Trading Central

5.365 / 6.0486Support & Resistance

Recent bullish events outweigh bearish events.

All events are bearish.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.